GlaxoSmithKline $13 billion acquisition of Novartis consumer healthcare joint venture stake

Overview:

• GlaxoSmithKline (GSK) is acquiring Novartis's stake in their consumer healthcare joint venture for $13 billion,
• The joint venture, which began in 2014, includes brands such as Nicotinell, Panadol Sensodyne and Voltaren.
• According to Reuters the deal follows GSK's ending of its bid to acquire Pfizer’s consumer healthcare business.

Sam Duke